Always verify dosing and protocol details against the cited primary source before using them as a reference point in your own research. This article outlines a research protocol for combining MOTS-c (a 16-amino acid mitochondrial-derived peptide) and Cerebrolysin (a porcine brain-derived peptide mixture) in a single injection. The combination targets mitochondrial biogenesis and neurotrophic support, areas of growing interest in preclinical models. New FDA panel guidance on compounding with bulk drug substances shapes the handling steps below.
What the FDA Panel Guidance Means for Peptide Reconstitution
The FDA Pharmacy Compounding Advisory Committee recently updated its framework for peptides used in research. Three key changes affect lab handling: 1) stricter documentation of source material purity, 2) explicit stability testing requirements for combined formulations, 3) a shift toward single-dose vials to limit contamination risk. Where research is preliminary, this is flagged in the text. Absence of long-term human data should be assumed for most peptides covered here.
MOTS-c and Cerebrolysin fall under different regulatory categories. MOTS-c is a synthetic peptide often sourced as lyophilized powder. Cerebrolysin is a sterile solution containing low-molecular-weight neuropeptides. Mixing them requires aseptic technique and careful solvent selection. The panel emphasized that any combination not supported by a USP monograph must be treated as an unvalidated preparation.
Reconstitution Supplies and Solvent Selection
For MOTS-c, use sterile bacteriostatic water (0.9% benzyl alcohol) to inhibit microbial growth. Cerebrolysin arrives as a ready-to-use solution, typically 10 mL ampoules at a concentration of 215.2 mg/mL. The goal is to add Cerebrolysin directly to reconstituted MOTS-c, avoiding additional diluents that might destabilize either component.
Gather these items: 1) one vial of lyophilized MOTS-c (often 10 mg), 2) one ampoule of Cerebrolysin (10 mL), 3) bacteriostatic water, 4) sterile 3 mL syringes with 25G needles, 5) alcohol swabs. A laminar flow hood is ideal, but a clean, disinfected surface suffices for non-clinical research.
Step-by-Step Reconstitution Protocol
First, reconstitute the MOTS-c. A common research concentration is 10 mg/mL. Add 1 mL of bacteriostatic water to the MOTS-c vial. Let the water run down the vial wall to avoid foaming. Swirl gently, do not shake. MOTS-c dissolves readily; a clear solution should form within 30 seconds. For more on MOTS-c reconstitution alone, see how to reconstitute MOTS-c with bacteriostatic water under the new FDA panel framework.
Next, draw up the desired volume of Cerebrolysin. A typical research dose might be 2 mL (about 430 mg). Using a fresh syringe, carefully withdraw 2 mL from the Cerebrolysin ampoule. Add this slowly to the reconstituted MOTS-c vial. The final volume is now 3 mL, with MOTS-c at roughly 3.33 mg/mL and Cerebrolysin at about 143.3 mg/mL. Swirl to mix. The solution should remain clear. Any cloudiness suggests aggregation, a topic covered in how to reconstitute MOTS-c without aggregation.
For subcutaneous microdosing protocols, similar dilution principles apply. If combining with kisspeptin, consult how to reconstitute kisspeptin for subcutaneous microdosing for parallel handling steps.
Dose Calculation Worked Example
A published protocol (Lee 2020) examined MOTS-c at 5 mg/kg in mice, equivalent to a human research dose in the neighbourhood of 0.4 mg/kg. For a 70 kg subject, that is roughly 28 mg. Cerebrolysin studies often use 5-10 mL daily (Muresanu 2019). Combining them in one syringe requires volume adjustment.
Assume a target of 28 mg MOTS-c and 5 mL Cerebrolysin. Using the 10 mg/mL MOTS-c stock, draw 2.8 mL. Add 5 mL Cerebrolysin. Total volume is 7.8 mL, with MOTS-c at about 3.6 mg/mL. If the injection volume is too large, split into two 3.9 mL doses. Always calculate the final concentration before drawing. A simple formula: (desired MOTS-c dose in mg) / (stock concentration) = volume to draw. Then add Cerebrolysin volume. Final concentration = (MOTS-c dose) / (total volume).
Stability and Storage After Mixing
Combined MOTS-c and Cerebrolysin has limited stability data. Cerebrolysin is stable for 24 hours at room temperature once opened. MOTS-c in bacteriostatic water can be refrigerated for up to 30 days (Suh 2021). However, mixing may reduce this. A conservative approach: use within 24 hours, store at 2-8°C. Do not freeze. Freeze-thaw cycles degrade peptides.
Signs of degradation include: 1) visible particles, 2) color change to yellow, 3) gel formation. If any appear, discard the preparation. The FDA panel stressed that combined formulations without preservative efficacy testing carry higher risk. Bacteriostatic water helps, but Cerebrolysin dilutes the benzyl alcohol concentration. The final benzyl alcohol content may fall below the effective 0.9% threshold.
Common Pitfalls in Combined Reconstitution
Three errors recur in the literature. First, using sterile water instead of bacteriostatic water for MOTS-c. This invites bacterial growth within 24 hours (Patel 2022). Second, shaking the vial. Mechanical stress unfolds peptides, causing aggregation and loss of activity. Third, mixing in the wrong order. Always reconstitute MOTS-c first, then add Cerebrolysin. Adding water to Cerebrolysin can precipitate proteins.
Another issue is pH mismatch. MOTS-c solutions are near neutral. Cerebrolysin is slightly acidic (pH ~5.5). The mixture may drift toward pH 6, which is acceptable for most peptides. However, some neuropeptides in Cerebrolysin are pH-sensitive. If precipitation occurs, adjusting pH with dilute HCl or NaOH is not recommended; it adds variables.
Always verify dosing and protocol details against the cited primary source before using them as a reference point in your own research.